Prelude(FRANCE) | $8,000,000 | (Nov 14, 2024)
Camouflet | $3,000,000 | (Nov 14, 2024)
CHAOS Industries | $145,000,000 | (Nov 14, 2024)
Certified by Founder
Lodge
Cedilla Therapeutics
start up
United States
- Cambridge, Massachusetts
- 25/10/2021
- Series B
- $25,000,000
For 60 years, sequence and structure has been the primary lens to understand protein function. It’s now time to look beyond and leverage the orchestration of protein function within cells.
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.
We are a driven and patient-focused team.
- Industry Biotechnology Research
- Website https://www.cedillatx.com/
- LinkedIn https://www.linkedin.com/company/cedillatherapeutics/
Related People
Alexandra (Sandra) GlucksmannFounder
United States -
Cambridge, Massachusetts,
I love working within a team to help build great biotech companies.
Arbolus | $20,000,000 | (Nov 14, 2024)
Trolley | $23,000,000 | (Nov 14, 2024)
Notabene | $14,500,000 | (Nov 14, 2024)
Pikndel | $1,000,000 | (Nov 14, 2024)
Zeplyn | $3,000,000 | (Nov 14, 2024)
High Basin Brands | $4,000,000 | (Nov 14, 2024)
Accelsius | $24,000,000 | (Nov 14, 2024)
Metsera | $215,000,000 | (Nov 14, 2024)
InVintory | $2,300,000 | (Nov 14, 2024)